7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Shares of Nordic Nanovector quadruple on high volumes in four days before profit taking took over, after it announced a definitive share exchange agreement to combine with Thor Medical, a fellow Norway-based privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, in an all-share transaction. 10 June 2023
San Diego, USA-base next-gen gene therapy developer Kate Therapeutics (KateTx) has emerged from stealth mode with a $51 million Series A financing. 9 June 2023
In mid-2014, the Kingdom of Saudi Arabia (KSA) faced one of the most daunting economic development challenges of its modern history, when crude oil prices collapsed by more than half. 9 June 2023
The Windsor Framework sets out a long-term solution for the supply of medicines into Northern Ireland as part of the revized agreement relating to the UK’s Brexit. 9 June 2023
The US Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) that has been submitted by US biotech Vertex Pharmaceutical. 9 June 2023
Sandoz, the generics and biosimilars unit of Novartis, has outlined an ambitious plan for its newly-independent future once the spin-out from its parent is complete. 9 June 2023
The US Food and Drug Administration (FDA) has published guidance entitled Clinical Drug Interactions Studies with Combined Oral Contraceptives. 9 June 2023
Anglo-Swedish pharma major AstraZeneca has entered into a collaboration, exclusive option and license agreement with privately-held UK biopharma Quell Therapeutics. 9 June 2023
With evolving patient pathways, advances in technology and surges of new data, traditional commercial models have been disrupted, and the expectations and preferences of healthcare providers (HCPs) have changed. 9 June 2023
Danish allergy expert ALK Abello (ALKB: DC) has reported positive Phase III results from a trial of its sublingual allergy immunotherapy tablet for the treatment of allergic rhinitis in children. 9 June 2023
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) yesterday voted unanimously 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in new-borns and infants born during or entering their first RSV season. 9 June 2023
German radiopharmaceutical biotech ITM Isotope Technologies has announced an equity investment round of 255 million euros ($273 million) led by Temasek. 9 June 2023
Russian pharmaceutical companies will receive additional subsidies from the state for the development of analogues of foreign drugs, as part of the current state plans for the reduction of import dependence in the country’s pharmaceutical sector, The Pharma Letter’s local correspondent reports. 9 June 2023
Privately-held US firms Aviko Radiopharmaceuticals and Neutron Therapeutics have announced the formation of a strategic partnership to advance boron neutron capture therapy (BNCT) to treat cancer. 8 June 2023
The Indian government is exploring the possibility of introducing a Production Linked Incentive (PLI) scheme for basic chemicals and active pharmaceutical ingredients (API) industries. 8 June 2023
The number of medicines recalled by manufacturers due to defects has increased 153% in the UK since 2017, according to new figures from the Medicines and Healthcare products Regulatory Agency (MHRA), with relaxed regulations during Covid one possible factor behind the increase. 8 June 2023
Californian biopharma FibroGen suffered a setback in part of its development of pamrevlumab, sending its shares 11% lower in Wednesday’s trading. 8 June 2023
Israeli generics giant Teva Pharmaceutical Industries said today that its US subsidiary has fully resolved its nationwide settlement agreement related to opioid claims. 8 June 2023
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics today revealed it has entered another strategic partnership with US pharma giant Pfizer (NYSE: PFE). 8 June 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024